Help them experience the possibilities of more frequent home hemodialysis.
Studies show that when prescribed more frequent home hemodialysis (typically 5 weekly treatments instead of 3), SNF residents have experienced:
- Longer survival1
- Fewer hospitalizations2
- Shorter post-dialysis recovery time.3
Click here to listen to SNF resident testimonials
Here’s What SNF Patients Say About Dialyzing More Frequently On-Site:
HHD Patient & NxStage Patient Advocate
Risks and Responsibilities
Patients and providers should review the following information carefully to decide whether home hemodialysis with NxStage systems is right for them.
Users may not experience the reported benefits of home, more frequent, or hemodialysis with the NxStage systems.
The NxStage systems require a prescription for use.
If a doctor prescribes more frequent home hemodialysis, vascular access is exposed to more frequent use, which may lead to access-related complications, including infection of the site. Doctors should evaluate the medical necessity of more frequent treatments and discuss the risks and benefits of more frequent therapy with users.
Patients and providers are encouraged to contact their state regulators to discuss state specific regulations that may impact dialysis in the Skilled Nursing Facility setting.
- Yang A, Lee WY, Hocking K, Xelay Acumen, Inc., Affiliated Dialysis. Survival comparison of daily home hemodialysis vs conventional dialysis in the nursing home setting. Nephrology News & Issues. February 17 2015.
- Weinhandl E, Hocking K, Markovich S, Vavrinchik S, Collins A. Increased Hemodialysis Frequency is Associated With Improved Clinical Outcomes Among Patients in Skilled Nursing Facilities. Abstract presented at ASN 2018.
- Bellin EY, Hellebrand AM, Kaplan SM, et al. Post-dialysis recovery time in ESRD patients receiving more frequent hemodialysis in skilled nursing facilities. Hemodial Int. 2022;(March):1-11. doi:10.1111/hdi.13012
© 2022 Fresenius Medical Care. All Rights Reserved. Fresenius Medical Care, the triangle logo, and NxStage are trademarks of Fresenius Medical Care Holdings, Inc. or its affiliated companies.
APM4697 Rev A